Page last updated: 2024-08-21

thiazoles and Hodgkin Disease

thiazoles has been researched along with Hodgkin Disease in 4 studies

Research

Studies (4)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's3 (75.00)24.3611
2020's1 (25.00)2.80

Authors

AuthorsStudies
Gopas, J; Gopinath, P; Muraleedharan, KM; Nandakumar, N1
Engert, A; Gasser, S; Hansen, HP; Reiners, KS; Sauer, M; von Strandmann, EP1
Borchmann, P; Engert, A; Monsef, I; Rancea, M; Skoetz, N; Will, A1
Bauer, K; Engert, A; Kluge, S; Kreuzer, KA; Monsef, I; Siebert, H; Skoetz, N1

Other Studies

4 other study(ies) available for thiazoles and Hodgkin Disease

ArticleYear
Benzisothiazolone Derivatives Exhibit Cytotoxicity in Hodgkin's Lymphoma Cells through NF-κB Inhibition and are Synergistic with Doxorubicin and Etoposide.
    Anti-cancer agents in medicinal chemistry, 2020, Volume: 20, Issue:6

    Topics: A549 Cells; Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Cell Movement; Doxorubicin; Drug Synergism; Etoposide; Hodgkin Disease; Humans; NF-kappa B; Thiazoles

2020
Induction of the DNA damage response by IAP inhibition triggers natural immunity via upregulation of NKG2D ligands in Hodgkin lymphoma in vitro.
    Biological chemistry, 2013, Volume: 394, Issue:10

    Topics: Blotting, Western; Cell Line, Tumor; DNA Damage; Enzyme-Linked Immunosorbent Assay; Flow Cytometry; Gene Expression Regulation, Neoplastic; Hodgkin Disease; Humans; Immunity, Innate; Inhibitor of Apoptosis Proteins; NK Cell Lectin-Like Receptor Subfamily K; Thiazoles; Tumor Necrosis Factor-alpha; Up-Regulation

2013
Fifteenth biannual report of the Cochrane Haematological Malignancies Group--focus on non-Hodgkin's lymphoma.
    Journal of the National Cancer Institute, 2013, Aug-07, Volume: 105, Issue:15

    Topics: Adult; Aged; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Bleomycin; Cyclophosphamide; Dasatinib; Doxorubicin; Etoposide; Hodgkin Disease; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Lymphoma, Non-Hodgkin; Middle Aged; Multicenter Studies as Topic; Multiple Myeloma; Neoplasm Staging; Piperazines; Platelet Transfusion; Prednisone; Primary Prevention; Procarbazine; Pyrimidines; Randomized Controlled Trials as Topic; Rituximab; Stem Cell Transplantation; Survival Analysis; Thiazoles; Thrombocytopenia; Transplantation, Autologous; Treatment Outcome; Vincristine; Vindesine

2013
Twelfth biannual report of the Cochrane Haematological Malignancies Group--focus on tyrosine kinase inhibitors.
    Journal of the National Cancer Institute, 2011, Feb-16, Volume: 103, Issue:4

    Topics: Adrenal Cortex Hormones; Aminoglycosides; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Cyclophosphamide; Dasatinib; Diphosphonates; Disease-Free Survival; Epoetin Alfa; Erythropoietin; Evidence-Based Medicine; Gemtuzumab; Graft vs Host Disease; Hematologic Neoplasms; Hodgkin Disease; Humans; Imatinib Mesylate; Interferon-alpha; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Methotrexate; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Randomized Controlled Trials as Topic; Recombinant Proteins; Rituximab; Stem Cell Transplantation; Thiazoles; Treatment Outcome; Vidarabine

2011